
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Recipient : Alvotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
Details : Mynzepli (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration.
Product Name : Mynzepli
Product Type : Protein
Upfront Cash : Inapplicable
August 21, 2025
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Recipient : Alvotech
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Immunology
Study Phase : Preclinical
Recipient : Alvotech
Deal Size : Undisclosed
Deal Type : Agreement
Alvotech and Advanz Enter into Supply and Commercialization Agreement for AVT10
Details : The agreement aims for the supply and commercialization of AVT10, Alvotech’s biosimilar candidate to Cimzia (certolizumab pegol).
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
July 01, 2025
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Recipient : Alvotech
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Canakinumab
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Recipient : Alvotech
Deal Size : Undisclosed
Deal Type : Agreement
Alvotech and Advanz Expand Partnership To Commercialize Three Biosimilars in Europe
Details : Advanz secures exclusive rights from Alvotech to commercialize three biosimilar candidates, Ilaris (canakinumab), Kesimpta (ofatumumab) and an undiclosed biosimilar in Europe.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
May 28, 2025
Lead Product(s) : Canakinumab
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Recipient : Alvotech
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Obeticholic Acid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ADVANZ PHARMA Responds to OCALIVA® EU Marketing Suspension Reversal
Details : Ocaliva (obeticholic acid) is a farnesoid X receptor (FXR) agonist, which is indicated for the treatment of individuals with primary biliary cholangitis.
Product Name : Ocaliva
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 02, 2024
Lead Product(s) : Obeticholic Acid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Recipient : Alvotech
Deal Size : Undisclosed
Deal Type : Agreement
Alvotech And Advanz Sign Agreement For Eylea Biosimilar In Europe
Details : Under the agreement, Alvotech will develop AVT06 (Aflibercept) biosimilar to Eylea. Advanz Pharma will be responsible for registration and commercializing in Europe, except for Germany and France.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
June 19, 2024
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : Alvotech
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cefepime,Enmetazobactam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
UK MHRA Approves Advanz Pharma Antibiotic for Complex Infections
Details : UK MHRA approved Exblifep (cefepime/enmetazobactam) antibiotic which is indicated to treat adults suffering from complicated UTIs and certain kinds of pneumonia acquired during hospital stays.
Product Name : Exblifep
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 05, 2024
Lead Product(s) : Cefepime,Enmetazobactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Study Phase : Preclinical
Recipient : Alvotech
Deal Size : $343.4 million
Deal Type : Partnership
Details : Advanz Pharma secures exclusive rights from Alvotech to commercialize AVT05, a biosimilar candidate to Simponi and Simponi Aria (golimumab), AVT16, a proposed biosimilar to Entyvio (vedolizumab), and three additional early-stage, undisclosed biosimilar c...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : $60.1 million
May 24, 2023
Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Recipient : Alvotech
Deal Size : $343.4 million
Deal Type : Partnership

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Paliperidone Palmitate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Palmeux (paliperidone palmitate) is a second-generation antipsychotic, also known as an atypical antipsychotic (simultaneous serotonin and dopamine antagonist) for the treatment of schizophrenia in adult patients.
Product Name : Palmeux
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 17, 2023
Lead Product(s) : Paliperidone Palmitate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Omalizumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Recipient : Alvotech
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair® (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand and Alvotech will be responsible for development a...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
February 06, 2023
Lead Product(s) : Omalizumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Recipient : Alvotech
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Govorestat
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Recipient : Applied Therapeutics
Deal Size : $138.4 million
Deal Type : Partnership
Details : AT-007 (gavorestat) is a central nervous system (CNS) penetrant Aldose Reductase inhibitor (ARI) in development for the treatment of several rare neurological diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $10.6 million
January 04, 2023
Lead Product(s) : Govorestat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Recipient : Applied Therapeutics
Deal Size : $138.4 million
Deal Type : Partnership
